API

Insulin Lispro (100IU/ml)

Drug classification

Antidiabetics (rapid-acting insulin analogue)

Dosage form

Solution for injection (pre-filled pen or vial).

API strength per dosage

100 IU/ml

Dose

Dose is individualized based on glycemic control; typical starting dose for adults and children is 0.2–0.4 units/kg/day, administered subcutaneously before meals. Dose adjustments required for renal or hepatic impairment. Frequent glucose monitoring is essential. Use with caution in elderly due to increased risk of hypoglycemia.

Mechanism of action

Binds to the insulin receptor (INSR), a transmembrane tyrosine kinase, activating its intrinsic kinase activity, leading to phosphorylation of insulin receptor substrates (IRS), which triggers the PI3K-Akt and MAPK pathways, promoting glucose uptake via GLUT4 translocation, glycogen synthesis, and inhibition of hepatic gluconeogenesis.

Indications

Treatment of Diabetes

Side effects

Hypoglycemia low blood glucose level

Pregnancy category

Precautions

Contraindications